Ser473
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > O-GlcNAc Site Page: > Ser473  -  Akt1 (human)

Site Information
RPHFPQFsysAsGtA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4261200

In vivo Characterization
Methods used to characterize site in vivo:
phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
lymphoma ( 1 ) , T cell lymphoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
RAD001 ( 1 )

References 

1

Witzig TE, et al. (2015) The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood 126, 328-35
25921059   Curated Info

2

Gandy JC, Rountree AE, Bijur GN (2006) Akt1 is dynamically modified with O-GlcNAc following treatments with PUGNAc and insulin-like growth factor-1. FEBS Lett 580, 3051-8
16684529   Curated Info